Federal Circuit Vacates ITC Ruling in AliveCor ECG Patent Dispute: A Lesson in Mootness

Case Overview

The Parties

The Patents at Issue

This pivotal case involved three U.S. patents covering innovations in cardiac arrhythmia monitoring and discordance tracking technologies:

• • US 9,572,499 B2 — Covering core ECG monitoring methods
• • US 10,638,941 B2 — Directed to arrhythmia tracking and scoring systems
• • US 10,595,731 B2 — Covering discordance monitoring methods and systems

The Accused Products and Technology

The accused products involved discordance monitoring systems and methods and systems for arrhythmia tracking and scoring — functionalities at the center of competition between consumer ECG platforms and integrated wearable ecosystems. The commercial stakes in this technology space are substantial, with market participants ranging from startups to global consumer electronics leaders.

Legal Representation

AliveCor was represented by Quinn Emanuel Urquhart & Sullivan, LLP, with attorneys Sean S. Pak and William Adams leading the appeal. The ITC was represented by its in-house legal team, including General Counsel Dominic L. Bianchi, advisors Panyin Hughes and Sidney A. Rosenzweig, and attorneys Cathy Chen and Wayne W. Herrington.

Litigation Timeline & Procedural History

The appeal was filed on February 15, 2023, in the District of Columbia circuit jurisdiction, before the Court of Appeals for the Federal Circuit — the exclusive appellate court for ITC patent determinations under 19 U.S.C. § 1337.

The case closed on March 7, 2025, after 751 days — a duration reflecting the complexity of appellate ITC review. The Federal Circuit’s jurisdiction over ITC appeals is exclusive, making it the singular venue for reviewing Section 337 patent findings at the appellate level.

The court ultimately resolved the matter not on the merits of infringement or patent validity, but on the threshold question of mootness — a procedural doctrine that extinguishes federal jurisdiction when the controversy ceases to present a live dispute.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a clear directive: “Accordingly, we vacate the Commission’s decision and remand with instructions to dismiss the case as moot.” No damages were awarded, and no permanent injunctive relief was granted, as the court never reached the substantive merits of the infringement claims under the three asserted patents.

Verdict Cause Analysis: The Mootness Doctrine in ITC Appeals

The court’s invocation of mootness is the most legally significant element of this decision. Under Article III of the U.S. Constitution, federal courts may only adjudicate live cases or controversies. When intervening events eliminate the practical effect of any possible ruling, courts are constitutionally required to dismiss or vacate rather than issue advisory opinions.

In the ITC context, mootness frequently arises from expiration of the relevant patents, cessation of importation of the accused products, consent orders, settlements, or statutory exclusion orders expiring before appellate resolution.

Legal Significance

This outcome reinforces the mootness doctrine’s potency as a case-dispositive mechanism in ITC patent appeals. Even a well-developed record before the Commission, including infringement findings and claim analysis, can be entirely nullified at the appellate stage by supervening mootness. The vacatur of the Commission’s decision also means that the underlying ITC ruling carries no precedential or preclusive effect.

Strategic Takeaways

For Patent Holders Pursuing ITC Relief:

• Assess the patent term runway before initiating or continuing Section 337 proceedings.
• Consider parallel district court actions to preserve damages claims that survive patent expiration.
• Monitor whether accused products continue to be imported throughout the appellate cycle.

For Accused Infringers and Respondents:

• Mootness arguments represent a powerful, low-cost appellate defense when circumstances warrant.
• Design-around strategies that eliminate the accused functionality may contribute to mootness arguments.

For R&D Teams:

• Freedom-to-operate (FTO) analyses in this space must account for active ITC proceedings, not merely issued patents.